ReviewCancer cell international2019
Mesenchymal stromal cells induce inhibitory effects on hepatocellular carcinoma through various signaling pathways.
Review in Cancer cell international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 28 citations in OpenAlex.
- Homing Assessment of Human Placenta-Derived Mesenchymal Stromal Cells in Immunodeficient NOG Mice Following Sublethal Irradiation.Advanced biomedical research · 2026Article
- FIB-3 index as a novel age-independent predictor of liver fibrosis and prognosis in hepatocellular carcinoma patients undergoing hepatectomy.Annals of gastroenterological surgery · 2025Article
- Single-cell transcriptomic analyses of tumor microenvironment and molecular reprograming landscape of metastatic laryngeal squamous cell carcinoma.Communications biology · 2024Article
- Stromal cells in the tumor microenvironment: accomplices of tumor progression?Cell death & disease · 2023Review
- Time- and Concentration-Dependent Effects of the Stem Cells Derived from Human Exfoliated Deciduous Teeth on Osteosarcoma Cells.Advanced biomedical research · 2023Article
- Mesenchymal stem cells-based therapy in liver diseases.Molecular biomedicine · 2022Review
- Mesenchymal stem/stromal cells in cancer therapy.Journal of hematology & oncology · 2021Review
- The role of mesenchymal stromal cells in immune modulation of COVID-19: focus on cytokine storm.Stem cell research & therapy · 2020Review
- Melatonin and Mesenchymal Stem Cells as a Key for Functional Integrity for Liver Cancer Treatment.International journal of molecular sciences · 2020Review
- Single sample scoring of hepatocellular carcinoma: A study based on data mining.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the most prevalent type of malignant liver disease worldwide. Molecular changes in HCC collectively contribute to Wnt/β-catenin, as a tumor proliferative signaling pathway, toll-like receptors (TLRs), nuclear factor-kappa B (NF-κB), as well as the c-Jun NH2-terminal kinase (JNK), predominant signaling pathways linked to the release of tumor-promoting cytokines. It should also be noted that the Hippo signaling pathway plays an important role in organ size control, particularly in promoting tumorigenesis and HCC development. Nowadays, mesenchymal stromal cells (MSCs)-based therapies have been the subject of in vitro, in vivo, and clinical studies for liver such as cirrhosis, liver failure, and HCC. At present, despite the importance of basic molecular pathways of malignancies, limited information has been obtained on this background. Therefore, it can be difficult to determine the true concept of interactions between MSCs and tumor cells. What is known, these cells could migrate toward tumor sites so apply effects via paracrine interaction on HCC cells. For example, one of the inhibitory effects of MSCs is the overexpression of dickkopf-related protein 1 (DKK-1) as an important antagonist of the Wnt signaling pathway. A growing body of research challenging the therapeutic roles of MSCs through the secretion of various trophic factors in HCC. This review illustrates the complex behavior of MSCs and precisely how their inhibitory signals interface with HCC tumor cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.